Latest Advances

  • Condition: Hormone Receptor-Positive vs. Hormone Receptor-Negative Breast Cancer
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Capecitabine
  • Number of Patients: 20934
  • Published —
This review of the literature explored the use of capecitabine in the treatment of patients with hormone receptor-positive versus hormone receptor-negative metastatic breast cancer.
  • Condition: Locally Advanced or Metastatic Breast Cancer
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: PARP (Poly ADP-Ribose Polymerase) Inhibitors
  • Number of Patients: 0
  • Published —
This review of the literature sought to determine the safety, effectiveness, and possible harms of poly(ADP-Ribose) polymerase (PARP) inhibitors in the treatment of patients with locally advanced or metastatic breast cancer.
  • Condition: Metastatic Triple-Negative Breast Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Sacituzumab Govitecan
  • Number of Patients: 468
  • Published —
The aim of this study was to evaluate sacituzumab govitecan as compared with single-agent chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
  • Condition: Metastatic Breast Cancer (MBC)
  • Journal: JAMA network open
  • Treatment Used: Weekly Paclitaxel with or without Oral Alisertib
  • Number of Patients: 174
  • Published —
This study compared paclitaxel alone versus paclitaxel plus alisertib in the treatment of patients with ER-positive and ERBB2-negative or triple-negative metastatic breast cancer (MBC).
  • Condition: Triple-Negative Breast Cancer (TNBC)
  • Journal: Current oncology reports
  • Treatment Used: Emerging Therapies
  • Number of Patients: 0
  • Published —
This article reviews the emerging therapies for patients with triple negative breast cancer (TNBC).
  • Condition: Metastatic Triple-Negative Breast Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Pembrolizumab vs. Chemotherapy
  • Number of Patients: 622
  • Published —
The aim of this study was to compared pembrolizumab with chemotherapy for second-line or third-line treatment of patients with metastatic triple-negative breast cancer.
  • Condition: Metastatic, Triple-Negative Breast Cancer
  • Journal: Breast cancer research : BCR
  • Treatment Used: Veliparib and Lapatinib
  • Number of Patients: 20
  • Published —
This study evaluated the safety and clinical activity of lapatinib and veliparib in patients with metastatic triple-negative breast cancer (TNBC).
  • Condition: Early Triple Negative Breast Cancer
  • Journal: Critical reviews in oncology/hematology
  • Treatment Used: Immunotherapy Addition to Neoadjuvant Chemotherapy (NACT)
  • Number of Patients: 1496
  • Published —
This review of the literature examined the use of neoadjuvant chemo-immunotherapy in the treatment of patients with early triple negative breast cancer (TNBC).
Showing 1-12 of 134